FDA Accepts Dupixent® (dupilumab) for Priority Review i

If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
There are approximately 160,000 patients in the U.S. living with eosinophilic... | April 4, 2022

Related Keywords

Japan , Paris , France General , France , Georged Yancopoulos , Regeneron Velocimmune , Prnewswire Regeneron Pharmaceuticals Inc , Regeneron Pharmaceuticals Inc , Twitter , Regeneron Genetics Center , Drug Administration , Dupilumab Development Program , Regeneron Velocimmune Technology , Nasdaq , Teva Pharmaceutical Industries Ltd , Exchange Commission , Euronext , Priority Review , Biologics License Application , Breakthrough Therapy , Orphan Drug , Eosinophilic Esophagitis , Dupixent Phase , Chief Scientific Officer George , Prescribing Informationincluding Patient , Forward Looking Statements , Regeneron Pharmaceuticals , Product Candidates , Teva Pharmaceutical Industries , Regeneron Pharmaceuticals Stock Exchange , News , Information , Press Release , F , Dupixent , Would , The , He , First , Medicine , Vailable , N , Syndicated , O , Treat , Eosinophilic , Esophagitis , Fire , Pproximately , Patients , Diving , Ith Regn Us75886f1075 ,